Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in proximal gastric or GEJ adenocarcinoma
NCT04631757Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label trial of camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04631757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631757.